We create tailor-made antibodies and assays to quantify unique biomarkers in a wide variety of neurodegenerative diseases and conditions such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. Our assays enable early detection before symptoms appear, providing valuable information from the drug development phase up to clinical practice, to improve the life of patients.
State-of-the-art biomarker assays for
neurodegenerative diseases
We create tailor-made antibodies and assays to quantify unique biomarkers in a wide variety of neurodegenerative diseases and conditions such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. Our assays enable early detection before symptoms appear, providing valuable information from the drug development phase up to clinical practice, to improve the life of patients.
Latest news and events
- We’re hiring!Join Our Team as a Business Officer! 📋 Do you…
- ADx and Fujirebio Join Forces with Biogen and Beckman Coulter to Advance Alzheimer’s Diagnostics
ADx and Fujirebio Join Forces with Biogen and Beckman Coulter to Advance Alzheimer’s Diagnostics
ADx, together with Fujirebio, is excited to announce a new… - ADx will join AAIC 2024
ADx will join AAIC 2024
We will be present at the 2024 edition of AAIC… - ADx will attend AD/PD 2024
ADx will attend AD/PD 2024
ADx is excited to attend AD/PD 2024 this year in… - Scientific articles in 2024
Scientific articles in 2024
In 2024, ADx remains committed to fostering collaborative efforts with… - We officially moved into our new offices!
We officially moved into our new offices!
More than a year ago our company was welcomed into…
Pharmaceutical companies
Biomarkers increase clinical trial success rate and help bring the right drugs to the right patient. Focus on drug development while we take care of the biomarkers. We build robust and reliable assays tailored to your needs, scaled up by our diagnostic partners and rolled out in time.
In Vitro Diagnostics Companies
We supply antibodies that meet the raw material requirements for IVD test kit manufacturing, and offer continuous support to develop and implement assays into easy-to-use kits for automated platforms, serving both the pharmaceutical companies and the clinic.
Our expertise
ADx bridges the gap between pharma and IVD companies, building partnerships to support innovations that can truly change the life of the patients with neurodegenerative conditions. Our management team combines more than 45 years of experience with an impressive track record developing superior diagnostic biomarkers.